Viral hepatitis has been a fundamental problem in Taiwan, especially hepatitis B. There is no cure for Hepatitis B and infected patients have to take medicine for the rest of their lives to control the virus.
The Disease Control Agency said that presently there are about 2.8-3.3 million hepatitis B virus carriers in Taiwan. Those carriers are 150 times more likely to develop liver cancer than healthy people.
A recent clinical research team led by Dr. Wu Ming-shun, director of the Department of Gastroenterology, Wanfang Hospital, found that supplementing Taiwan-specific Arthrospira when treating patients with hepatitis B can effectively reduce the hepatitis B surface antigen (anti-HBs).
This clinical trial is still ongoing, and it awaits publication in medical journals. Taiwan-specific Arthrospira FEM-102, in the non-clinical trials, has shown to be effective in increasing immunity and resistance to virus infections. Currently, Arthrospira FEM-102 is being developed by the domestic industry into dietary supplements.
Wanfang Hospital’s Gastroenterology team recruited 60 volunteers infected with Hepatitis B to participate in the test. In addition to drugs, the patients were administered different doses of Arthrospira FEM-102. After 6 months, blood tests found that patients taking 6 grams of FEM-102 daily showed a significant reduction in hepatitis B surface antigen (anti-HBs).
Current medication cannot eliminate hepatitis B completely. Only a small portion of infected childer can be completely cured. The rest of the patients are facing life-long intake of anti-viral drugs to control hepatitis B virus. Often, the older the patient, the harder it is to control hepatitis.
The emergence of the unique Arthrospira FEM-102 brings new hope to hepatitis B patients, especially those over 50 with the chronic form of hepatitis.